Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01934504

Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) — AAV  

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Clinical Trial

Official title:
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)

Clinical Trial Summary

The goal of the study is to find biological markers (certain proteins or cellular markers found in a blood test) that will inform doctors which patients diagnosed with ANCA-associated vasculitis (AAV) are most likely to be able to stop their medications suppressing their immune systems and remain in remission.

Clinical Trial Description

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are small vessel vasculitides that typically follow a chronic course and are associated with serious illness and death.Three clinical conditions are recognized: microscopic polyangiitis (MPA); granulomatosis with polyangiitis (Wegener's, GPA); and eosinophilic granulomatosis with polyangiitis (EPA, formerly Churg Strauss Syndrome). Though these conditions have different clinical features, they can have overlapping immunological characteristics.

The precise cause of AAV is not understood, but there are clear genetic associations which, in the context of predisposing environmental factors, such as infections, may lead to development of disease. There are no diagnostic criteria for AAV, but there are validated classification criteria and disease definitions.

There is a need to find biological markers that define immunological tolerance so that immunotherapy medicines may be correctly changed and safely withdrawn in some people. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Vasculitis
Clinical Trial Details
NCT number NCT01934504
Study type Observational
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Terminated
Phase N/A
Start date December 2013
Completion date February 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Completed NCT05988008 - A Study of CCX168 in Japanese and Caucasian Healthy Adult Males Phase 1
Active, not recruiting NCT02198248 - Low-dose Glucocorticoid Vasculitis Induction Study Phase 4
Completed NCT06004960 - A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Withdrawn NCT01275287 - Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Phase 2
Not yet recruiting NCT04871191 - Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Phase 2
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Not yet recruiting NCT06226662 - Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Phase 2
Terminated NCT02749292 - Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Phase 4
Terminated NCT02294344 - The Clinical Efficacy of DFPP in Patients With AAGN N/A
Withdrawn NCT01275274 - Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Phase 2
Completed NCT06004947 - A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications Phase 1
Recruiting NCT05969522 - Stratified Therapy on Pediatric AAGN Phase 4
Recruiting NCT03323476 - Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Phase 3
Completed NCT05988021 - A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 Phase 1
Recruiting NCT06056921 - Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease Phase 1
Not yet recruiting NCT02180126 - Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation N/A
Recruiting NCT06294236 - Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) Phase 1
Not yet recruiting NCT06379646 - An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease N/A